You are here: Industry Insights > AbbVie

News List

AbbVie gets orphan drug and fast track status for elezanumab pharmaceutical-technology
October 09, 2020
AbbVie has received orphan drug and fast track designations from the US Food and Drug Administration (FDA) for elezanumab (ABT-555) to treat spinal cord injury (SCI).
Top 20 global pharma companies by MCap saw 10.2 per cent rise in MCap in Q2 2020: GlobalData expresspharma
September 24, 2020
Johnson & Johnson maintained its top position with MCap growth of 7.2 per cent on a QoQ basis.
AbbVie, I-Mab Enter Global Immuno-Oncology Alliance contractpharma
September 07, 2020
AbbVie to pay as much as $1.74 billion for Lemzoparlimab, one of I-Mab's leading drug candidates for the treatment of multiple cancers.
AbbVie, Harvard University collaborate for research on emergent viral diseases expresspharma
August 31, 2020
This collaboration aims to rapidly integrate fundamental biology into the preclinical and clinical development of new therapies for viral diseases that address a variety of therapeutic modalities.
AbbVie teams up with Harvard University for viral disease therapies pharmaceutical-technology
August 27, 2020
AbbVie has entered into a research collaboration with Harvard University to evaluate and develop new therapies for the treatment of emergent viral infections.
AbbVie & Harvard University Form Research Alliance contractpharma
August 27, 2020
AbbVie and Harvard University have announced a $30 million collaborative research alliance, launching a multi-pronged effort at Harvard Medical School (HMS) to study and develop novel therapies against emergent viral infections ...
AbbVie's Skyrizi stands to gain as docs move away from older psoriasis meds—Amgen's Otezla included fiercepharma
August 26, 2020
In an increasingly crowded psoriasis market, a raft of next-gen biologics is looking to topple an older suite of drugs for sales supremacy.
AbbVie Submits Regulatory Application to FDA for Rinvoq for Ankylosing Spondylitis americanpharmaceuticalreview
August 26, 2020
AbbVie has submitted an application for a new indication to the U.S. Food and Drug Administration (FDA) for Rinvoq™ (upadacitinib; 15 mg, once daily), a selective and reversible JAK inhibitor, for the treatment of adult patients with ...
Top Pharma & Biopharma Quarterly Results contractpharma
August 26, 2020
Pfizer: 2Q Revenues: $11.8 billion (-11%). 2Q Earnings: $3.4 billion (-32%). YTD Revenues: $23.8 billion (-10%). YTD Earnings: $6.8 billion (-24%)...
Financial Report: Abbvie contractpharma
August 12, 2020
Revenues in the quarter up 26% boosted by Immunology portfolio and Allergan aesthetics portfolio.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page